申请人:Memory Pharmaceuticals Corporation
公开号:EP2336128A1
公开(公告)日:2011-06-22
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods and use thereof.
wherein
A is
本发明一般涉及烟碱乙酰胆碱受体(nACh 受体)的配体、nACh 受体的活化以及与烟碱乙酰胆碱受体缺陷或功能失调相关的疾病(尤其是脑部疾病)的治疗领域。此外,本发明还涉及作为α7 nACh受体亚型配体的新型化合物(如吲唑类和苯并噻唑类)、制备此类化合物的方法、含有此类化合物的组合物及其使用方法。
其中
A 是